Ligand Pharma (LGND) Tops Q1 EPS by $1.42; Offers FY23 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Ligand Pharma (LGND) Tops Q1 EPS by $1.42; Offers FY23 Guidance

Ligand Reports First Quarter 2023 Financial Results

May 4, 2023 4:01 PM EDT

2023 Financial Guidance Raised

Conference Call Begins at 4:30 p.m. Eastern Time Today

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.

2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue... More